Alterations of total non stimulated salivary flow in patients with squamous cell carcinoma of the mouth and oropharynx submitted to hyperfractionated radiation therapy
Autor(a) principal: | |
---|---|
Data de Publicação: | 2004 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Revista Brasileira de Cancerologia (Online) |
Texto Completo: | https://rbc.inca.gov.br/index.php/revista/article/view/2043 |
Resumo: | Prevention and early diagnosis are actually the most effective measures that we dispose to improve the prognostic of the malignant tumors. The mouth and oropharynx tumors are treated with success, when early diagnosed. The radiotherapy is almost always one of the selected treatments for these tumors. When cancer is diagnosed in advanced stages, many a time the treatment needs to be carried out swiftly to be efficient, and consequently the radiotherapists use the hyperfractionated therapy, with the patient receiving two lower doses of radiation in two sessions daily, amounting to a higher daily dosage, of about 160cGy/2x/day. When the major salivary glands are present in the radiated field, the xerostomia appears by the second week of treatment (1500 to 2000 cGy), changing the patient's health, and causing difficulties for him to eat, speak and sleep. The objective of this study was to evaluate the quantitative alterations of the total non stimulated salivate flow of patients who underwent hyperfractionated therapy for the treatment of squamous cell carcinoma of mouth and oropharynx. Samples of twelve male patients' saliva from Erasto Gaertner Hospital in Curitiba, Paraná, Brazil, were examined. Two samples of saliva were collected from each patient, the first one before the beginning of the radiotherapy, and the second at the end of the treatment. As a result, we obtained salivary loss in 91.7% of the patients, with a percentage of total salivary flow loss of 62.9%, registered in the second collection. We concluded that the hyperfractionated therapy causes a marked xerostomia when the major salivary glands are in the radiated field. |
id |
INCA-1_da769408ad4104f48cf21a02ac444a97 |
---|---|
oai_identifier_str |
oai:rbc.inca.gov.br:article/2043 |
network_acronym_str |
INCA-1 |
network_name_str |
Revista Brasileira de Cancerologia (Online) |
repository_id_str |
|
spelling |
Alterations of total non stimulated salivary flow in patients with squamous cell carcinoma of the mouth and oropharynx submitted to hyperfractionated radiation therapyAlterações do fluxo salivar total não estimulado em pacientes portadores de carcinoma espinocelular de boca e orofaringe submetidos à radioterapia por hiperfracionamentoNeoplasias OrofaríngeasNeoplasias BucaisRadioterapia HiperfracionadaGlândulas SalivaresXerostomiaOropharyngeal NeoplasmsMouth NeoplasmsHyperfractionated RadiotherapySalivary GlandsXerostomiaPrevention and early diagnosis are actually the most effective measures that we dispose to improve the prognostic of the malignant tumors. The mouth and oropharynx tumors are treated with success, when early diagnosed. The radiotherapy is almost always one of the selected treatments for these tumors. When cancer is diagnosed in advanced stages, many a time the treatment needs to be carried out swiftly to be efficient, and consequently the radiotherapists use the hyperfractionated therapy, with the patient receiving two lower doses of radiation in two sessions daily, amounting to a higher daily dosage, of about 160cGy/2x/day. When the major salivary glands are present in the radiated field, the xerostomia appears by the second week of treatment (1500 to 2000 cGy), changing the patient's health, and causing difficulties for him to eat, speak and sleep. The objective of this study was to evaluate the quantitative alterations of the total non stimulated salivate flow of patients who underwent hyperfractionated therapy for the treatment of squamous cell carcinoma of mouth and oropharynx. Samples of twelve male patients' saliva from Erasto Gaertner Hospital in Curitiba, Paraná, Brazil, were examined. Two samples of saliva were collected from each patient, the first one before the beginning of the radiotherapy, and the second at the end of the treatment. As a result, we obtained salivary loss in 91.7% of the patients, with a percentage of total salivary flow loss of 62.9%, registered in the second collection. We concluded that the hyperfractionated therapy causes a marked xerostomia when the major salivary glands are in the radiated field.A prevenção e o diagnóstico precoces são atualmente, as medidas mais eficazes de que dispomos para melhorar o prognóstico dos tumores malignos. Os tumores de boca e orofaringe são tratados com sucesso quando descobertos precocemente. A radioterapia é quase sempre um dos tratamentos de eleição para estes tumores. Quando as neoplasias são diagnosticadas em estádios mais avançados, o tratamento muitas vezes necessita ser mais rápido para ser eficiente, e com isso os radioterapeutas lançam mão do hiperfracionamento, no qual o paciente recebe duas doses diárias de radiação, com dose diária menor por fração, mas maior ao dia, ficando em cerca de 160cGy/2x/dia. Quando as glândulas salivares maiores estão presentes no campo irradiado, a xerostomia torna-se presente já na segunda semana de tratamento (1500 a 2000 cGy), alterando a saúde geral do paciente, que fica com dificuldade para se alimentar, falar e dormir. O objetivo deste estudo foi avaliar as alterações quantitativas do fluxo salivar total não estimulado de pacientes que se submetem ao hiperfracionamento para tratamento de carcinoma espinocelular de boca e orofaringe. Foram avaliadas as amostras de saliva de doze pacientes do Hospital Erasto Gaertner, de Curitiba, Paraná, pacientes esses do sexo masculino. Foram coletadas duas amostras de saliva, a primeira antes da radioterapia e a segunda, ao término do tratamento. Como resultado, obtivemos perda salivar em 91,7% dos pacientes, com uma porcentagem de perda de fluxo salivar total de 62,9%, registrada na segunda coleta. Concluindo, o hiperfracionamento ocasiona xerostomia bastante acentuada quando as glândulas salivares maiores encontram-se presentes no campo irradiado.INCA2004-06-30info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArtigos, Avaliado pelos paresapplication/pdfhttps://rbc.inca.gov.br/index.php/revista/article/view/204310.32635/2176-9745.RBC.2004v50n2.2043Revista Brasileira de Cancerologia; Vol. 50 No. 2 (2004): Apr./May/June; 103-108Revista Brasileira de Cancerologia; Vol. 50 Núm. 2 (2004): abr./mayo/jun.; 103-108Revista Brasileira de Cancerologia; v. 50 n. 2 (2004): abr./maio/jun.; 103-1082176-9745reponame:Revista Brasileira de Cancerologia (Online)instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)instacron:INCAporhttps://rbc.inca.gov.br/index.php/revista/article/view/2043/1261Guebur, Maria Isabela Rapoport, Abrão Sassi, Laurindo Moacir Oliveira, Benedito Valdecir de Pereira, José Carlos Gasparin Ramos, Gyl Henrique Albrecht info:eu-repo/semantics/openAccess2021-11-29T20:33:23Zoai:rbc.inca.gov.br:article/2043Revistahttps://rbc.inca.gov.br/index.php/revistaPUBhttps://rbc.inca.gov.br/index.php/revista/oairbc@inca.gov.br0034-71162176-9745opendoar:2021-11-29T20:33:23Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)false |
dc.title.none.fl_str_mv |
Alterations of total non stimulated salivary flow in patients with squamous cell carcinoma of the mouth and oropharynx submitted to hyperfractionated radiation therapy Alterações do fluxo salivar total não estimulado em pacientes portadores de carcinoma espinocelular de boca e orofaringe submetidos à radioterapia por hiperfracionamento |
title |
Alterations of total non stimulated salivary flow in patients with squamous cell carcinoma of the mouth and oropharynx submitted to hyperfractionated radiation therapy |
spellingShingle |
Alterations of total non stimulated salivary flow in patients with squamous cell carcinoma of the mouth and oropharynx submitted to hyperfractionated radiation therapy Guebur, Maria Isabela Neoplasias Orofaríngeas Neoplasias Bucais Radioterapia Hiperfracionada Glândulas Salivares Xerostomia Oropharyngeal Neoplasms Mouth Neoplasms Hyperfractionated Radiotherapy Salivary Glands Xerostomia |
title_short |
Alterations of total non stimulated salivary flow in patients with squamous cell carcinoma of the mouth and oropharynx submitted to hyperfractionated radiation therapy |
title_full |
Alterations of total non stimulated salivary flow in patients with squamous cell carcinoma of the mouth and oropharynx submitted to hyperfractionated radiation therapy |
title_fullStr |
Alterations of total non stimulated salivary flow in patients with squamous cell carcinoma of the mouth and oropharynx submitted to hyperfractionated radiation therapy |
title_full_unstemmed |
Alterations of total non stimulated salivary flow in patients with squamous cell carcinoma of the mouth and oropharynx submitted to hyperfractionated radiation therapy |
title_sort |
Alterations of total non stimulated salivary flow in patients with squamous cell carcinoma of the mouth and oropharynx submitted to hyperfractionated radiation therapy |
author |
Guebur, Maria Isabela |
author_facet |
Guebur, Maria Isabela Rapoport, Abrão Sassi, Laurindo Moacir Oliveira, Benedito Valdecir de Pereira, José Carlos Gasparin Ramos, Gyl Henrique Albrecht |
author_role |
author |
author2 |
Rapoport, Abrão Sassi, Laurindo Moacir Oliveira, Benedito Valdecir de Pereira, José Carlos Gasparin Ramos, Gyl Henrique Albrecht |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Guebur, Maria Isabela Rapoport, Abrão Sassi, Laurindo Moacir Oliveira, Benedito Valdecir de Pereira, José Carlos Gasparin Ramos, Gyl Henrique Albrecht |
dc.subject.por.fl_str_mv |
Neoplasias Orofaríngeas Neoplasias Bucais Radioterapia Hiperfracionada Glândulas Salivares Xerostomia Oropharyngeal Neoplasms Mouth Neoplasms Hyperfractionated Radiotherapy Salivary Glands Xerostomia |
topic |
Neoplasias Orofaríngeas Neoplasias Bucais Radioterapia Hiperfracionada Glândulas Salivares Xerostomia Oropharyngeal Neoplasms Mouth Neoplasms Hyperfractionated Radiotherapy Salivary Glands Xerostomia |
description |
Prevention and early diagnosis are actually the most effective measures that we dispose to improve the prognostic of the malignant tumors. The mouth and oropharynx tumors are treated with success, when early diagnosed. The radiotherapy is almost always one of the selected treatments for these tumors. When cancer is diagnosed in advanced stages, many a time the treatment needs to be carried out swiftly to be efficient, and consequently the radiotherapists use the hyperfractionated therapy, with the patient receiving two lower doses of radiation in two sessions daily, amounting to a higher daily dosage, of about 160cGy/2x/day. When the major salivary glands are present in the radiated field, the xerostomia appears by the second week of treatment (1500 to 2000 cGy), changing the patient's health, and causing difficulties for him to eat, speak and sleep. The objective of this study was to evaluate the quantitative alterations of the total non stimulated salivate flow of patients who underwent hyperfractionated therapy for the treatment of squamous cell carcinoma of mouth and oropharynx. Samples of twelve male patients' saliva from Erasto Gaertner Hospital in Curitiba, Paraná, Brazil, were examined. Two samples of saliva were collected from each patient, the first one before the beginning of the radiotherapy, and the second at the end of the treatment. As a result, we obtained salivary loss in 91.7% of the patients, with a percentage of total salivary flow loss of 62.9%, registered in the second collection. We concluded that the hyperfractionated therapy causes a marked xerostomia when the major salivary glands are in the radiated field. |
publishDate |
2004 |
dc.date.none.fl_str_mv |
2004-06-30 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Artigos, Avaliado pelos pares |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rbc.inca.gov.br/index.php/revista/article/view/2043 10.32635/2176-9745.RBC.2004v50n2.2043 |
url |
https://rbc.inca.gov.br/index.php/revista/article/view/2043 |
identifier_str_mv |
10.32635/2176-9745.RBC.2004v50n2.2043 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://rbc.inca.gov.br/index.php/revista/article/view/2043/1261 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
INCA |
publisher.none.fl_str_mv |
INCA |
dc.source.none.fl_str_mv |
Revista Brasileira de Cancerologia; Vol. 50 No. 2 (2004): Apr./May/June; 103-108 Revista Brasileira de Cancerologia; Vol. 50 Núm. 2 (2004): abr./mayo/jun.; 103-108 Revista Brasileira de Cancerologia; v. 50 n. 2 (2004): abr./maio/jun.; 103-108 2176-9745 reponame:Revista Brasileira de Cancerologia (Online) instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA) instacron:INCA |
instname_str |
Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA) |
instacron_str |
INCA |
institution |
INCA |
reponame_str |
Revista Brasileira de Cancerologia (Online) |
collection |
Revista Brasileira de Cancerologia (Online) |
repository.name.fl_str_mv |
Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA) |
repository.mail.fl_str_mv |
rbc@inca.gov.br |
_version_ |
1797042249409757184 |